Vanda Pharmaceuticals develops and sells therapies for high unmet medical needs, including HETLIOZ for non-24-hour sleep-wake disorders and Fanapt for schizophrenia. The company is also working on developing products for other disorders like jet lag, autism spectrum, gastroparesis, and oncology. Founded in 2002 and headquartered in Washington, Vanda Pharmaceuticals markets its products across the United States, Europe, and Israel.